Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
Ines Pires daSilvaTasnia AhmedJennifer Leigh McQuadeCaroline A NebhanJohn J ParkJudith M VersluisPatricio Serra-BellverYasir KhanTim SlatteryHoney K OberoiSelma UgurelLauren E HayduRudolf HerbstJochen UtikalClaudia PföhlerPatrick TerheydenMichael WeichenthalRalf GutzmerPeter MohrRajat RaiJessica L SmithRichard A ScolyerAna M AranceLisa PickeringJames M G LarkinPaul C LoriganChristian U BlankDirk SchadendorfMichael A DaviesMatteo S CarlinoDouglas B JohnsonGeorgina V LongSerigne N LôAlexander M MenziesPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Newly developed combinations of routinely collected baseline clinical factors predict the response and survival outcomes of patients with metastatic melanoma treated with immunotherapy and may serve as valuable tools for clinical decision making.
Keyphrases